Two cancer experts have been named to lead Mount Sinai’s new Tisch Cancer Hospital, which is under development and expected to open in 2027. Cardinale B. Smith, MD, PhD, has been appointed Chief Medical Officer and Vice President of Cancer Clinical Affairs, and Ash Tewari, MBBS, MCh, has been appointed Surgeon-in-Chief.
A Focus on Equity
Dr. Smith will oversee clinical operations and quality of the new inpatient oncology units at the Tisch Cancer Hospital and inpatient cancer care elsewhere throughout the health system. In addition, she will integrate oncology clinical care within the ambulatory and inpatient settings across the health system with the Tisch Cancer Institute’s research and teaching missions.
Cardinale B. Smith, MD, PhD
Ash Tewari, MBBS, MCh
Dr. Smith, whose other roles at Mount Sinai Health System have included Chief Quality Officer for Oncology, has demonstrated continued excellence in leadership, research, and patient outcomes since her appointment to the faculty in 2010. A highly regarded research scientist with a robust grant portfolio supported by the National Institutes of Health and the American Cancer Society, Dr. Smith works with her interdisciplinary research team to improve the quality of care for patients with cancer, with a focus on underrepresented populations and developing novel models of equitable cancer care delivery.
A Trailblazer in Robotic Surgery
Dr. Tewari will be responsible for provider aspects of daily operations for surgical oncology inpatients at the Tisch Cancer Hospital. He will ensure integration among inpatient surgical oncology, the Tisch Cancer Hospital, and departmental research and teaching missions.
A pioneer in robotic surgery, Dr. Tewari has been involved in developing robotic prostatectomy from its inception. Dr. Tewari, who is Chair of the Milton and Carroll Petrie Department of Urology at the Icahn School of Medicine at Mount Sinai, is one of a few robotic surgeons to be awarded research grants from the National Institutes of Health and the Department of Defense, including an R01 grant for which he served as the principal investigator, researching the utility of multiphoton microscopy during prostate cancer treatment.
